Related references
Note: Only part of the references are listed.UCSF ChimeraX: Structure visualization for researchers, educators, and developers
Eric F. Pettersen et al.
PROTEIN SCIENCE (2021)
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
Mika Kamata-Sakurai et al.
CANCER DISCOVERY (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
Naomi Dempsey et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
A general Fc engineering platform for the next generation of antibody therapeutics
Da Chen et al.
THERANOSTICS (2021)
Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment
Traian Sulea et al.
MABS (2020)
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment
Rena Liu et al.
ANTIBODIES (2020)
Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function
Maximilian Brinkhaus et al.
JOURNAL OF IMMUNOLOGY (2020)
Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display
Ellen K. Wagner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Mapping pH at Cancer Cell Surfaces
Da Wei et al.
MOLECULAR IMAGING AND BIOLOGY (2019)
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston et al.
NATURE (2019)
An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence
Chang-Han Lee et al.
NATURE COMMUNICATIONS (2019)
Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice
Andrew Kroetsch et al.
MABS (2019)
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
Tae Hyun Kang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Affimer proteins inhibit immune complex binding to Fc gamma RIIIa with high specificity through competitive and allosteric modes of action
James I. Robinson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Thomas D. Goddard et al.
PROTEIN SCIENCE (2018)
Identification of high affinity HER2 binding antibodies using CHO Fab surface display
Annalee W. Nguyen et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2018)
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Megan Lo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Designing binding kinetic assay on the bio-layer interferometry (BLI) biosensor to characterize antibody-antigen interactions
Vishal Kamat et al.
ANALYTICAL BIOCHEMISTRY (2017)
Tumour acidosis: from the passenger to the driver's seat
Cyril Corbet et al.
NATURE REVIEWS CANCER (2017)
IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions
Chang-Han Lee et al.
NATURE IMMUNOLOGY (2017)
Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma
Anderson H. Webb et al.
BMC CANCER (2017)
Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
Alysia A. Ahmed et al.
JOURNAL OF STRUCTURAL BIOLOGY (2016)
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Lindsay B. Avery et al.
MABS (2016)
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
Gabrielle Romain et al.
BLOOD (2014)
In Vivo Maps of Extracellular pH in Murine Melanoma by CEST-MRI
Delli D. Castelli et al.
MAGNETIC RESONANCE IN MEDICINE (2014)
Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
Sang Taek Jung et al.
ACS CHEMICAL BIOLOGY (2013)
Acidic extracellular microenvironment and cancer
Yasumasa Kato et al.
CANCER CELL INTERNATIONAL (2013)
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
Futa Mimoto et al.
MABS (2013)
Tuning gene expression with synthetic upstream open reading frames
Joshua P. Ferreira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
pH sensing and regulation in cancer
Mehdi Damaghi et al.
FRONTIERS IN PHYSIOLOGY (2013)
Crosstalk between Human IgG Isotypes and Murine Effector Cells
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2012)
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
Tsunehiro Mizushima et al.
GENES TO CELLS (2011)
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Margaret E. Ackerman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Dysregulated pH: a perfect storm for cancer progression
Bradley A. Webb et al.
NATURE REVIEWS CANCER (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents
Oleg A. Andreev et al.
MOLECULAR MEMBRANE BIOLOGY (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors
Stephen L. Sazinsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epi-CHO, an episomal expression system for recombinant protein production in CHO cells
R Kunaparaju et al.
BIOTECHNOLOGY AND BIOENGINEERING (2005)
Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells
G Berntzen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition
FA Fellouse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching
CA Sarkar et al.
NATURE BIOTECHNOLOGY (2002)
Regulated expression and inhibitory function of FcγRIIb in human monocytic cells
S Tridandapani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex
P Sondermann et al.
NATURE (2000)
Share Paper
